Lv31
328 积分 2025-07-01 加入
Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness
6天前
已完结
Early Emicizumab Treatment in Acquired Hemophilia A: Impact on Bypassing Agent Use and Length of Hospitalization in an Australian Single-Center Cohort
6天前
已完结
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group
1个月前
已完结
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
1个月前
已完结
Sweet’s Syndrome
2个月前
已完结
Hemophagocytic Lymphohistiocytosis
2个月前
已完结
Pulmoanry sarcoidosis
3个月前
已完结
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
8个月前
已完结
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy
1年前
已完结
皖公网安备34019202002308
